Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313852) titled 'A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia' on Dec. 30, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
B-cell Acute Lymphoblastic Leukemia
B-Cell Acute Lymphoblastic Leukemia, Adult
B-ALL
Intervention:
Drug: Blinatumomab Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 2026
Target Sample Size: 26
Countries of Recru...